With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of treating two disparate conditions, one of which is the target of Merck’s fast ...

In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the ...

Diagonal Therapeutics is taking shape, launching with $128 million and backed by the likes of BVF Partners, Atlas Venture and RA Capital to develop a pipeline of antibody agonists. The company will ...

Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced financial consultant. She has a demonstrated ...